Oncolytics Biotech Inc (ONCY)

$0.84 +0.04 (5.16%)
Market Cap 107.51M
Revenue (ttm) 0.00
Net Income (ttm) -28.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 545,000
Avg Vol 1,175,338
Day's Range N/A - N/A
Shares Out 127.51M
Stochastic %K 79%
Beta 1.13
Analysts Strong Sell
Price Target $4.42

Company Profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (“GI”) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored...

Industry: Biotechnology
Sector: Healthcare
Phone: 403 670 7377
Fax: 403 283 0858
Address:
4350 Executive Drive, Suite 325, San Diego, United States
cbachand
cbachand Aug. 24 at 3:36 AM
$ONCY https://ir.oncolyticsbiotech.com/wp-content/uploads/2025/09/Oncolytics_August_2026_Investor_Presentation.pdf
0 · Reply
JohnnyC63
JohnnyC63 Aug. 23 at 11:50 PM
$ONCY Haven't reviewed it yet... just an FYI for the board https://ir.oncolyticsbiotech.com/wp-content/uploads/2025/09/Oncolytics_August_2026_Investor_Presentation.pdf
3 · Reply
GoPatzGo123
GoPatzGo123 Aug. 23 at 2:02 PM
$ONCY Does anyone anticipate a press release this week? We are nearing the end of August, and there has been no indication of a partnership, while other biotech companies are experiencing significant share price soaring...When might we expect our turn? Jared you were brought in for a reason...lets execute and get er done
1 · Reply
GoPatzGo123
GoPatzGo123 Aug. 21 at 8:00 PM
$ONCY the oncology sector heating up with rumours of takeovers. I remember this was under 2 bucks now trending #1 $SLS We are still under a buck...
1 · Reply
De_man
De_man Aug. 21 at 6:17 PM
$ONCY well look.at.that . Wainwright just lowered the price target to 5 dollars. Just a little lower than the 200+ that noteable says we are worth. Good thing note knows more than all the analysts combined.
3 · Reply
FonsieTrader
FonsieTrader Aug. 21 at 4:28 PM
$ONCY Continues to advance the development of pelareorep, its oncolytic immunotherapy. On August 18, the company received written feedback from the FDA aligning on a potential registrational path for pelareorep in second-line RAS-mutant, microsatellite-stable (MSS) metastatic colorectal cancer, as part of the REO 033 study. Key points: • Alignment on a potential accelerated approval pathway based on objective response rate • Progression-free survival (PFS) positioned as the basis for full approval • Clear path to expand the ongoing randomized study into a pivotal Part B Today the stock is finally starting to digest the latest developments. Pelareorep continues to be developed as an immunotherapy platform focused primarily on gastrointestinal cancers. FDA news source: http://finance.yahoo.com/healthcare/art… More information: http://oncolyticsbiotech.com Communicated disclaimer: http://stockresearchtoday.com/oncy/
1 · Reply
JBuyer
JBuyer Aug. 21 at 3:15 PM
$ALLO $ONCY $SLS $VSTM The shorting of ground breaking cures for Cancer and Autoimmune diseases should not be allowed- or least until they are profitable for one year. But in my mind, NOT AT ALL!!
2 · Reply
FonsieTrader
FonsieTrader Aug. 21 at 3:01 PM
$ONCY Oncolytics Biotech recently received written feedback from the FDA aligning on a potential registrational path for pelareorep in second-line RAS-mutant, microsatellite-stable (MSS) metastatic colorectal cancer. Key points from the FDA alignment: • Potential accelerated approval pathway based on objective response rate • Progression-free survival (PFS) positioned as the basis for full approval • Clear path to expand the ongoing randomized REO 033 study (Part A) into a pivotal Part B Pelareorep is a first-in-class double-stranded RNA oncolytic immunotherapy. It selectively replicates in tumor cells and activates both the innate and adaptive immune systems, helping to convert “cold” tumors into “hot” ones. The company continues to advance this platform primarily in gastrointestinal cancers. Source: http://finance.yahoo.com/healthcare/art… More information: http://oncolyticsbiotech.com Communicated disclaimer: http://stockresearchtoday.com/oncy
0 · Reply
FonsieTrader
FonsieTrader Aug. 21 at 1:56 PM
$ONCY Price is holding the rising support line at $0.8075 after the recent pullback. Market cap sits near $103M. The bigger story remains the regulatory progress from earlier this week. Oncolytics received written FDA feedback confirming alignment on a potential pivotal Part B expansion of REO 033. The path supports response rate for accelerated approval and PFS for full approval, building directly on the ongoing randomized trial. Three Fast Tracks remain active. Part A data still expected by year-end. Support is holding. The registration path is clearer. Still early. #ONCY #Biotech #Immunotherapy Communicated disclaimer: http://stockresearchtoday.com/oncy/
0 · Reply
CaseyLe
CaseyLe Aug. 21 at 1:47 PM
$ONCY Purchasing 💅
1 · Reply
Latest News on ONCY
Oncolytics price target lowered to $5 from $10 at H.C. Wainwright

2026-08-19T10:05:26.000Z - 4 days ago

Oncolytics price target lowered to $5 from $10 at H.C. Wainwright

Oncolytics aligns with FDA on path for REO 033 expansion study

2026-08-18T13:16:14.000Z - 5 days ago

Oncolytics aligns with FDA on path for REO 033 expansion study

Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer

Aug 18, 2026, 9:00 AM EDT - 5 days ago

Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer

Oncolytics Biotech Quarterly report: Q2 2026

Aug 12, 2026, 7:00 AM EDT - 11 days ago

Oncolytics Biotech Quarterly report: Q2 2026

Oncolytics announces FDA Fast Track designation for pelareorep

2026-07-20T13:06:01.000Z - 4 weeks ago

Oncolytics announces FDA Fast Track designation for pelareorep

Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer

Jul 20, 2026, 9:00 AM EDT - 4 weeks ago

Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer

Oncolytics provides clinical, regulatory update on REO 033

2026-07-13T13:10:54.000Z - 5 weeks ago

Oncolytics provides clinical, regulatory update on REO 033

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial

Jul 13, 2026, 9:00 AM EDT - 5 weeks ago

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial

Oncolytics secures new patent for pelareorep manufacturing

2026-06-16T13:38:20.000Z - 2 months ago

Oncolytics secures new patent for pelareorep manufacturing

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

Jun 16, 2026, 9:00 AM EDT - 2 months ago

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

Oncolytics Biotech Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 12:50 PM EDT - 2 months ago

Oncolytics Biotech Transcript: Jefferies Global Healthcare Conference 2026

Oncolytics promotes John McAdory to COO

2026-06-02T14:21:34.000Z - 2 months ago

Oncolytics promotes John McAdory to COO

CGON

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer

Jun 2, 2026, 9:00 AM EDT - 2 months ago

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer

Oncolytics announces initial data from pelareorep combination study

2026-06-01T13:47:40.000Z - 2 months ago

Oncolytics announces initial data from pelareorep combination study

Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches

Jun 1, 2026, 9:00 AM EDT - 2 months ago

Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches

Oncolytics Biotech Slides: Investor presentation

Jun 1, 2026, 7:00 AM EDT - 2 months ago

Oncolytics Biotech Slides: Investor presentation

Oncolytics Biotech to present data at ASCO 2026 on pelareorep

2026-05-22T13:45:50.000Z - 3 months ago

Oncolytics Biotech to present data at ASCO 2026 on pelareorep

Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors

May 22, 2026, 9:00 AM EDT - 3 months ago

Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors

Oncolytics Biotech Quarterly report: Q1 2026

May 14, 2026, 4:00 PM EDT - 3 months ago

Oncolytics Biotech Quarterly report: Q1 2026

Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer

May 4, 2026, 9:00 AM EDT - 3 months ago

Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer

Oncolytics says in alignment with FDA following pelareorep Type C meeting

2026-04-27T13:19:05.000Z - 4 months ago

Oncolytics says in alignment with FDA following pelareorep Type C meeting

Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study

Apr 27, 2026, 8:10 AM EDT - 4 months ago

Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study

Oncolytics Biotech Slides: Investor presentation

Apr 27, 2026, 7:00 AM EDT - 4 months ago

Oncolytics Biotech Slides: Investor presentation

Oncolytics price target lowered to $5 from $7 at Lake Street

2026-04-07T14:24:37.000Z - 4 months ago

Oncolytics price target lowered to $5 from $7 at Lake Street

Oncolytics schedules FDA meeting for pelareorep registrational path

2026-04-06T13:56:11.000Z - 4 months ago

Oncolytics schedules FDA meeting for pelareorep registrational path

Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer

Apr 6, 2026, 9:00 AM EDT - 4 months ago

Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer

Oncolytics completes domicile change to the U.S.

2026-04-01T13:39:37.000Z - 5 months ago

Oncolytics completes domicile change to the U.S.

Oncolytics Biotech® Completes Domicile Change to the United States

Apr 1, 2026, 9:00 AM EDT - 5 months ago

Oncolytics Biotech® Completes Domicile Change to the United States

Oncolytics Biotech Registration statement: Registration filing

Apr 1, 2026, 8:00 AM EDT - 5 months ago

Oncolytics Biotech Registration statement: Registration filing

Oncolytics files $250M mixed securities shelf

2026-04-01T10:11:38.000Z - 5 months ago

Oncolytics files $250M mixed securities shelf

Oncolytics Biotech Annual report: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 5 months ago

Oncolytics Biotech Annual report: Q4 2025

Oncolytics to present new data on Pelareorep at AACR 2026

2026-03-19T13:16:47.000Z - 5 months ago

Oncolytics to present new data on Pelareorep at AACR 2026

Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026

Mar 19, 2026, 9:00 AM EDT - 5 months ago

Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026

Oncolytics Biotech Slides: Corporate presentation

Mar 3, 2026, 6:00 AM EST - 6 months ago

Oncolytics Biotech Slides: Corporate presentation

Oncolytics initiates randomized colorectal cancer study

2026-03-02T14:12:44.000Z - 6 months ago

Oncolytics initiates randomized colorectal cancer study

Oncolytics Biotech® Launches Randomized Colorectal Cancer Study

Mar 2, 2026, 9:00 AM EST - 6 months ago

Oncolytics Biotech® Launches Randomized Colorectal Cancer Study

Oncolytics concludes enrollment in GOBLET study

2026-02-24T14:05:55.000Z - 6 months ago

Oncolytics concludes enrollment in GOBLET study

Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer

Feb 24, 2026, 9:00 AM EST - 6 months ago

Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer

Oncolytics receives FDA Fast Track Designation for pelareorep

2026-02-04T13:55:27.000Z - 7 months ago

Oncolytics receives FDA Fast Track Designation for pelareorep

Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer

Feb 4, 2026, 8:50 AM EST - 7 months ago

Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer

Oncolytics Biotech® Announces Results of Special Meeting of Shareholders

Jan 15, 2026, 4:01 PM EST - 7 months ago

Oncolytics Biotech® Announces Results of Special Meeting of Shareholders

Oncolytics Biotech Transcript: AGM 2026

Jan 15, 2026, 10:00 AM EST - 7 months ago

Oncolytics Biotech Transcript: AGM 2026

Oncolytics appoints John McAdory as EVP, strategy and operations

2026-01-14T14:15:39.000Z - 7 months ago

Oncolytics appoints John McAdory as EVP, strategy and operations

CGON

Oncolytics Biotech Slides: Investor presentation

Jan 14, 2026, 7:00 AM EST - 7 months ago

Oncolytics Biotech Slides: Investor presentation

Oncolytics announces updates data from GOBLET cohort 4

2026-01-12T14:10:53.000Z - 7 months ago

Oncolytics announces updates data from GOBLET cohort 4

Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

Jan 12, 2026, 9:00 AM EST - 7 months ago

Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

Oncolytics outlines strategic rationale for proposal to change jurisdiction

2026-01-09T14:05:19.000Z - 8 months ago

Oncolytics outlines strategic rationale for proposal to change jurisdiction

Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada

Jan 9, 2026, 9:00 AM EST - 8 months ago

Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada

Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings

Jan 8, 2026, 9:00 AM EST - 8 months ago

Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings

Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris

Jan 7, 2026, 9:00 AM EST - 8 months ago

Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris

Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer

Dec 16, 2025, 9:00 AM EST - 8 months ago

Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer

Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada

Dec 9, 2025, 6:00 PM EST - 9 months ago

Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada

Oncolytics Biotech® Provides Update on Special Meeting of Shareholders

Nov 20, 2025, 4:05 PM EST - 9 months ago

Oncolytics Biotech® Provides Update on Special Meeting of Shareholders

Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

Nov 19, 2025, 9:00 AM EST - 9 months ago

Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

Oncolytics Biotech Earnings release: Q3 2025

Nov 11, 2025, 6:00 PM EST - 10 months ago

Oncolytics Biotech Earnings release: Q3 2025

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

Oct 28, 2025, 7:30 AM EDT - 10 months ago

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

Oct 20, 2025, 9:00 AM EDT - 10 months ago

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study

Sep 29, 2025, 8:30 AM EDT - 11 months ago

Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study

Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion

Sep 16, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

Sep 8, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

Sep 2, 2025, 9:10 AM EDT - 1 year ago

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

Aug 28, 2025, 8:30 AM EDT - 1 year ago

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

Oncolytics Biotech Registration statement: Registration Filing

Aug 22, 2025, 8:00 AM EDT - 1 year ago

Oncolytics Biotech Registration statement: Registration Filing

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Aug 11, 2025, 4:55 PM EDT - 1 year ago

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Oncolytics Biotech Transcript: AGM 2025

Aug 8, 2025, 10:00 AM EDT - 1 year ago

Oncolytics Biotech Transcript: AGM 2025

Oncolytics Biotech Earnings release: Q2 2025

Aug 8, 2025, 10:00 AM EDT - 1 year ago

Oncolytics Biotech Earnings release: Q2 2025

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

Aug 8, 2025, 9:05 AM EDT - 1 year ago

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

Aug 8, 2025, 9:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results

Aug 5, 2025, 8:30 AM EDT - 1 year ago

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End

Jul 29, 2025, 8:30 AM EDT - 1 year ago

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

Jul 23, 2025, 9:39 AM EDT - 1 year ago

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules

Jul 22, 2025, 3:32 PM EDT - 1 year ago

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules

Oncolytics Biotech Transcript: Status Update

Jul 22, 2025, 1:00 PM EDT - 1 year ago

Oncolytics Biotech Transcript: Status Update

Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types

Jul 16, 2025, 8:30 AM EDT - 1 year ago

Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers

Jul 10, 2025, 8:30 AM EDT - 1 year ago

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

Jul 8, 2025, 8:30 AM EDT - 1 year ago

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

Jun 30, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

Jun 11, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

May 23, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

Oncolytics Biotech Earnings Call Transcript: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Oncolytics Biotech Earnings Call Transcript: Q1 2025

Oncolytics Biotech Earnings release: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Oncolytics Biotech Earnings release: Q1 2025

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

May 14, 2025, 4:01 PM EDT - 1 year ago

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

May 6, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

Apr 24, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Apr 10, 2025, 6:09 PM EDT - 1 year ago

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

Apr 10, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

Oncolytics Biotech Earnings Call Transcript: Q4 2024

Mar 7, 2025, 8:30 AM EST - 1 year ago

Oncolytics Biotech Earnings Call Transcript: Q4 2024

Oncolytics Biotech Annual report: Q4 2024

Mar 7, 2025, 8:30 AM EST - 1 year ago

Oncolytics Biotech Annual report: Q4 2024

Oncolytics Biotech Earnings release: Q4 2024

Mar 7, 2025, 8:30 AM EST - 1 year ago

Oncolytics Biotech Earnings release: Q4 2024

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

Mar 7, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

cbachand
cbachand Aug. 24 at 3:36 AM
$ONCY https://ir.oncolyticsbiotech.com/wp-content/uploads/2025/09/Oncolytics_August_2026_Investor_Presentation.pdf
0 · Reply
JohnnyC63
JohnnyC63 Aug. 23 at 11:50 PM
$ONCY Haven't reviewed it yet... just an FYI for the board https://ir.oncolyticsbiotech.com/wp-content/uploads/2025/09/Oncolytics_August_2026_Investor_Presentation.pdf
3 · Reply
GoPatzGo123
GoPatzGo123 Aug. 23 at 2:02 PM
$ONCY Does anyone anticipate a press release this week? We are nearing the end of August, and there has been no indication of a partnership, while other biotech companies are experiencing significant share price soaring...When might we expect our turn? Jared you were brought in for a reason...lets execute and get er done
1 · Reply
GoPatzGo123
GoPatzGo123 Aug. 21 at 8:00 PM
$ONCY the oncology sector heating up with rumours of takeovers. I remember this was under 2 bucks now trending #1 $SLS We are still under a buck...
1 · Reply
De_man
De_man Aug. 21 at 6:17 PM
$ONCY well look.at.that . Wainwright just lowered the price target to 5 dollars. Just a little lower than the 200+ that noteable says we are worth. Good thing note knows more than all the analysts combined.
3 · Reply
FonsieTrader
FonsieTrader Aug. 21 at 4:28 PM
$ONCY Continues to advance the development of pelareorep, its oncolytic immunotherapy. On August 18, the company received written feedback from the FDA aligning on a potential registrational path for pelareorep in second-line RAS-mutant, microsatellite-stable (MSS) metastatic colorectal cancer, as part of the REO 033 study. Key points: • Alignment on a potential accelerated approval pathway based on objective response rate • Progression-free survival (PFS) positioned as the basis for full approval • Clear path to expand the ongoing randomized study into a pivotal Part B Today the stock is finally starting to digest the latest developments. Pelareorep continues to be developed as an immunotherapy platform focused primarily on gastrointestinal cancers. FDA news source: http://finance.yahoo.com/healthcare/art… More information: http://oncolyticsbiotech.com Communicated disclaimer: http://stockresearchtoday.com/oncy/
1 · Reply
JBuyer
JBuyer Aug. 21 at 3:15 PM
$ALLO $ONCY $SLS $VSTM The shorting of ground breaking cures for Cancer and Autoimmune diseases should not be allowed- or least until they are profitable for one year. But in my mind, NOT AT ALL!!
2 · Reply
FonsieTrader
FonsieTrader Aug. 21 at 3:01 PM
$ONCY Oncolytics Biotech recently received written feedback from the FDA aligning on a potential registrational path for pelareorep in second-line RAS-mutant, microsatellite-stable (MSS) metastatic colorectal cancer. Key points from the FDA alignment: • Potential accelerated approval pathway based on objective response rate • Progression-free survival (PFS) positioned as the basis for full approval • Clear path to expand the ongoing randomized REO 033 study (Part A) into a pivotal Part B Pelareorep is a first-in-class double-stranded RNA oncolytic immunotherapy. It selectively replicates in tumor cells and activates both the innate and adaptive immune systems, helping to convert “cold” tumors into “hot” ones. The company continues to advance this platform primarily in gastrointestinal cancers. Source: http://finance.yahoo.com/healthcare/art… More information: http://oncolyticsbiotech.com Communicated disclaimer: http://stockresearchtoday.com/oncy
0 · Reply
FonsieTrader
FonsieTrader Aug. 21 at 1:56 PM
$ONCY Price is holding the rising support line at $0.8075 after the recent pullback. Market cap sits near $103M. The bigger story remains the regulatory progress from earlier this week. Oncolytics received written FDA feedback confirming alignment on a potential pivotal Part B expansion of REO 033. The path supports response rate for accelerated approval and PFS for full approval, building directly on the ongoing randomized trial. Three Fast Tracks remain active. Part A data still expected by year-end. Support is holding. The registration path is clearer. Still early. #ONCY #Biotech #Immunotherapy Communicated disclaimer: http://stockresearchtoday.com/oncy/
0 · Reply
CaseyLe
CaseyLe Aug. 21 at 1:47 PM
$ONCY Purchasing 💅
1 · Reply
FonsieTrader
FonsieTrader Aug. 21 at 1:30 PM
$ONCY Oncolytics Biotech is a clinical-stage biotech developing pelareorep, a first-in-class oncolytic immunotherapy. Pelareorep is a double-stranded RNA virus that: • Selectively replicates in cancer cells • Activates both innate and adaptive immune responses • Helps turn “cold” tumors into “hot” ones The company is primarily focused on gastrointestinal cancers (colorectal, pancreatic, and anal). Recent highlight: Oncolytics received written FDA feedback aligning on a potential registrational path for pelareorep in second-line RAS-mutant MSS metastatic colorectal cancer (REO 033 study). This platform technology continues to show promise in advancing immunotherapy options for solid tumors with high unmet need. Source: https://ir.oncolyticsbiotech.com Communicated disclaimer: https://stockresearchtoday.com/oncy/
0 · Reply
saxy4u
saxy4u Aug. 21 at 1:01 PM
$ONCY shot across the Big Pharma! https://lnkd.in/p/g489fuDe
0 · Reply
saxy4u
saxy4u Aug. 21 at 12:58 PM
$ONCY https://lnkd.in/p/gkQS6SWX
0 · Reply
GoPatzGo123
GoPatzGo123 Aug. 20 at 8:12 PM
$ONCY anyone remeber when the last time this went up over a dime?
1 · Reply
JohnnyC63
JohnnyC63 Aug. 20 at 7:16 PM
$ONCY Look in the mirror, with open heart and soul, and eyes filled with integrity, and tell me ONCY stock is NOT heavily manipulated. Of course, greedy narcissistic sociopaths don't give two hoots about integrity, so I know where this request is going to go. Ducks are lining up... soon!!
1 · Reply
saxy4u
saxy4u Aug. 20 at 6:49 PM
$ONCY can someone e just sell at market 30000 shares? Watch what happens, it will go up $.05 to $.10. These algorithms can’t handle it
0 · Reply
Condenser
Condenser Aug. 20 at 6:19 PM
$ONCY opened short pos @0.83 - change back to long around 0.75 me thinks Nfa
1 · Reply
NoName_1
NoName_1 Aug. 20 at 5:45 PM
$ONCY what are you smoking saxy? Must be the same stuff as Ole notable💩
0 · Reply
saxy4u
saxy4u Aug. 20 at 4:07 PM
$ONCY 👇👇👇👇don’t put stop loss that’s how they manipulate the price! Put sell order at $10
2 · Reply
MadMaverick
MadMaverick Aug. 20 at 3:46 PM
⚡ $ONCY Follow-Up 🚨The Setup🚨 Price Action: Trading between $0.85 – $1.10 Catalysts: Strong preclinical RAS-combo data + FDA Fast Track for lead asset pelareorep Following the $MRNA playbook (which exploded +177% in a day on its Phase 3 cancer vaccine readout).$ONCY is a much smaller, earlier-stage version of that same immuno-oncology thesis. Key Levels 🛑 Invalidation: Below $0.75 (Trade is dead) 🛡️ Support: $0.86 🎯 Resistance: $1.19 Risk Note Micro-caps mean binary risk and thin liquidity. Protect profits, set stops, and prioritize consistency over greed. Communicated Disclaimer - https://stockresearchtoday.com/oncy/
0 · Reply
FoxM07
FoxM07 Aug. 20 at 2:09 PM
$ONCY Jefferies is only engaged in a complete dilution process. The exposed paid pumper is regurgitating an old and dim argument where he/she believes Jefferies was brought on board to handle the bidding for Oncy that is going on between RVMD, Merck and Roche. A spectacularly stupid pump that was immediately dismissed. Oncy has zero BP interest at the moment as evidenced by the languishing SP.
0 · Reply
Notable_Ex
Notable_Ex Aug. 20 at 1:50 PM
$ONCY A competitive bidding process is what Jefferies LLC. has been engaged to conduct.
0 · Reply